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Phototherapy is highly effective in the therapy of 
psoriasis, but patient access to phototherapeutic fa-
cilities is not universal. Commercial tanning facilities 
are universal, but their efficacy in psoriasis treatment 
is unestablished. Our purpose was to conduct a study 
to assess the effect of a commercial tanning unit 
outfitted with nonprescription lamps on psoriasis. 
We conducted a 6-wk open study of20 adult patients 
with stable psoriasis vulgaris. Clinical response was 
defined as a decrease in the Psoriasis Area Severity 
Index (PAS I) or the Self-Administered P ASI (SAP ASI) 
by 2:10%. There were 16 men and 4 women who 
participated with a mean (±SD) age of 43.0 ± 14.8 y. 
Initial and final health-related quality of life infor-
mation collected included the following instruments: 
the Brief Symptom Inventory (BSI), the Psoriasis-
Related Stressor Scale (PRSS), and the Psoriasis Dis-
ability Scale (PDS). Side effects of tanning therapy 
were closely monitored. Fifteen subjects completed 
the entire 6-wk trial, and exit data on all subjects 
were used for analysis. The mean number of tanning 
sessions was 19 ± 7.6 with a median of19 and range of 
P h.otother.·ap.y w ith artificial light sources represe_· nts one of the most important therapeutic advances in psoriasis treatment in the twentieth century (Weinstein and Gottleib, 1993; Farber, 1995; Greaves and Weinstein, 1995). Unfortunately, phototherapy is often unavailable 
in rural areas, and expense precludes some pa tients from visiting 
these fac iliti es. By contrast, commercia l tanning facilities are uni-
versa l. [n 1992 it was estimated that one mil lion Americ;ms visited 
tanning salon s on any given day (DeLeo, 1994) 
lt is traditionally taught that tanning bed or solarium light is 
ine ffective for psoriasis treatment. Studies have demonstrated that 
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3 to 29. Analysis of all 20 enrolled subjects found that 
16 (80%) showed clinical response as measured by 
PASI, whereas 17 (85%) showed SAPASI response. 
Initial and final PASI scores decreased (p = 0 .0001) 
from 7.96 ± 1.77 to 5.04 ± 2.5, and SAPASI scores also 
decreased (p = 0.02) from 11.8 ± 4.4 to 7.9 ± 7 .7 . 
When controlled for age and sex, a dose-response 
relationship was demonstrated with the PASI and 
SAPASI (p < 0.02). Decreases in the mean BSI and 
PRSS scales were demonstrated (p < 0.02), confirm-
ing the clinical significance of the reductions in 
disease severity scores. Episodes of mild burning 
occurred in 7 of 20 (35%) participants. Three subjects 
reported itching after one or two tanning sessions. 
This study showed that a tested com.mercial nonpre-
scription tanning unit improved both psoriasis sever-
ity and health- related quality of life. Commercial 
tanning bed treatments may be a useful approach in 
patients unable to obtain office-based ultraviolet 
treatments. Key words: plrototiJerapylultl'aviolet A a11d B . 
J I11vest Dem1atol 109:170-174, 1997 
ultraviolet A (UV A) does no t add to the known benefits of 
ultraviolet B (UVB) phototherapy (Doer el a/, 1981; Diette e1 a/, 
1984). Accordingly, dermatologists admonish their patients that 
nonprescription tanning devices arc of no benefit in psoriasis 
therapy. Lowe (1992) summarized the traditiona.l thinking in his 
sta tement: "The use of UV A tanning salon treatments in the 
therapy of psoriasis is usuall y unsuccessful. . .. " 
Parish (1977) found that UVA treatment of psoriasis sites (4 X 5 
em) led to clinical improvement in 9 of 10 patients treated. Diffey 
(1986) , in his survey of tanning sa lon pa trons , reported that of 22 
clients who employed indoor tanning to treat the ir psoriasis, 17 
(77%) were co mp.lete ly satisfied and 5 (23 %) were partially satisfied 
with th is therapeutic modality. Moreove r, in a recent survey of318 
psoriasis patients, we fo und that 68'X, of those who had tried 
no nprescription tanning bed therapy believed this modality was 
effective (Fleischer cl a/ 1996a). To test the hypothesis that non-
prescription tanning beds can be an effective modality in the 
treatment of moderate severity psoriasis, we designed and con-
du cted a clinical trial. 
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Table I. Phototherapy Schedules Used in Study 
Treatment (min) 
Skin W eek Week Week Week W eek Week 
Type 1 2 3 4 5 6 
2 4 ·1 0 15 20 25 
II 3 7 15 20 25 30 
Ill 3 7 IS 20 25 30 
MATERJALS AND METHODS 
Protocol T he research protoco l was approved by the Bowman Gray 
School of Medicine C linical P...esearch Practices Committee . Writte n in-
formed consent was o btained from all particip<lnts . 
Tanning Equipment and Treatments Phototherapy equipment con-
sisted of a commercial tanrting bed o utfi tted with BdJarium S lamps. This 
nonpresc ription lamp outputs high-intens ity UV A and has 4.6% of the tota l 
o utput as uvn . 
Data on File: Wolff Systems Technology (Atlanta, GA) Moreover, 
this lamp was fo und to be the most common lamp in commercial tanning 
fac ilities in a survey stud y conducted in North Carolina (Fleischer et t1 /, 
1993). 
All phototherapy sessions were administered in a uni versity setting by a 
phototherapy technician o r experienced physician assistant. Subjects re-
ceived three to fiv e t<Hming treatments per week fo r 6 wk of the study. T he 
variability in numbers of sessions per week was chosen to simulate typica l 
community tanning bed usc. Initial and subsequent pho totherapy dosing 
was performed with a schedule based upon self-reported slcin type (Wein-
stock, 1992) {Table 1). Modification of recommendations of the manuf.l c-
turer were required because WolfFTcchno logy does not recommend usc for 
type I skin. Because dosimetry in commercial tanning f.1c ili ties is not based 
upon UV irradiancc n1casurcs and is stric tly confined to ti_tn i.ng n1casures, to 
approx itnatc con1nntnity tanning fac iliti es . we also based trca tn1cnt duration 
upon time . Because o f the limi tations of our UV light meters, we did not 
quantify the UVA and UVB light exposure from this uni t. 
To minimize the po tential confounding influence of ambient solar 
exposure, this tria l was condu cted in the winter and early sp ring from 
November 1, 1995, through April 14 , 1996. Fourteen patients completed 
the tria l by January 1, 1996. Aside from emo ll.i ents and coa l tar that patients 
were using at the tin1c of cnro lln1cnt, no other psoriasis treacn1ents \Vcrc 
allowed. 
Psoriasis Severity Assess1nents T he Pso riasis Area Severity lndex 
(PAS!) and the Self- Administered PAS! (SAPASI) were performed on all 
particip:mts at the study initiation and upon weekly completion of their 
phototherapy sessions. Deta il ed descriptions of these in struments and their 
validity arc available (Fredriksson and Pette rsson , 1978; Fle ischer ct nl, 1994; 
Fleischer and Exum, 1995; Feldman el a/, 1996). C linica l response was 
defined as a decrease of 2: 10% in the PASJ or SAP AS I score, and clearan ce 
was defined as a PAS I. or SAP ASI score of zero. Subjects also completed a 
subjective assessment of the change in psoriasis sf!verity by completing a 
1 00-mm Visual Ana log Scale (VAS) with the following anchors: 0 = "much 
Worse," 50 = uno change." and 1 00 = "n1uch better." 
Inclusion and Exclusion Criteria Study inclusion criteria included the 
following: dermatologist diagnosis of psoriasis vulgaris, age 2: 18 y, wi lling-
ness to forgo changes in psoriasis thcrapcuric rcgin1ent, and psorio1sis seve rity 
of 2: 5 on the PASI scale. A PASJ score of 2: 5 was chosen to select fo r 
subj ects with moderate to severe psoriasis (l' le ischer ct n/1996b) (Fleische r 
et nl 1996a); clin ica ll y these subjects would be candidates fo r UV Light 
treatments. The SAPAS I score has also been defined as moderate when the 
score is greate r than 3 (Fle ischer et nl 1 996b). 
Exclusion criteria included : currentl y pregnant or intending to become 
pregnant during the study; concurrent physician o r home-admittistered UV 
therap y, tanning bed visits, o r phototherapy in the past 3 wk; rapidl y 
worsen.ing psoriasis: history of herpes labial is induced by sunlight o r artifi cial 
light sources; signi ficant unrelated medical condi tions or laboratory abnor-
mal.ities that would prevent completion of the study or increase the ri sk of 
an adverse reaction. To reduce the possibility of bias from other therapeutic 
modalities, subjects were excl uded if any new psoriasis therapies (including 
emoll ient therap y) were used in the past 3 wk or if subjects used an)' ora l 
antibiotics in the past 2 wk. No change in other therapies was al.lowed . 
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Subject Demographics and Previous Exposure Attributes T here 
were 16 men and four women who participated with a mean( :!:: SD) age o f 
43.0 :!:: 14.8 y and range of 26-74 y. Self-reported skin types were as 
fo llows: type I, six participants; type II , six participants; type Ill , eight 
participants . O ur subjects had a history of psoriasis fo r an average of 14.3 y. 
Seven subjects had previo usly used tannin g beds in the treatment of their 
psoriasis an average of 3 mo each. and six of these repo rted tha t it had 
previous ly he lped their condition. Seven of nine subjects who had previ-
o usly been treated with UVB or psora len photochemotherapy reported that 
these treatments had helped. Sevcllteen of 20 subjects reported that solar 
irtadiation helps their disease. 
Quality of Life Assessments Initial and final hea lth-related q uali ty of 
li fe information collected included the followin g instruments: 
(i) The 53-item Brief Symptom In ventory (BSI): a measure of psychiatri c 
symptom severi ty (Derogati s and Spencer, 1982). 
(ii) T he 20-itcm Psoriasis-Related Stressor Scale (Pl~SS): a measure of 
stressful aspects of psoriasis develo ped at tl1e Bowman Gray School o f 
Medicine (SR Rapp , ML Exum, SR Feldman, AB Fleischer, OM Rebous-
sin, AR C la rk , unpublished data). 
(i ii) The 14-item Perce ived Stress Scale: a measure of psychologic stress 
(Cohen ct nl, '1983). 
(iv) T he 36-itcm Psoriasis Disability Sca le: a measure of psoriasis-related 
functional and social disability . ' 
Side Effect Profiles To determine the acute side efFects of tanning 
therapy, we ass~sscd phototoxic reactions (burns) and rashes objectively by 
physical examination and subjective ly assessed itching at each visit. We 
subjectively graded all phototoxic reactions as mild , moderate. o r severe. 
Subjective Satisfaction To obtain an estimate of subjec t sa risf.1ction 
with tltis protocol, a series of questions presented as VAS was administered 
at the study completion. Questions assessed sa tisf.1ction, whe tl1 er the subject 
would recommend tl1i s trea tment moda li ty to a fri end with psoriasis, and a 
global side effect pro fil e . 
RESULTS 
Three-Fourths of the Participants Cmnpleted the Study 
Fifteen subj ects comple te d th e study to the full 6 wk of the rapy. 
T h e oth e r fiv e subj ec ts had e xi t severity and h ealth-re lated qu a li ty 
of life data collecte d at the ir last visit. Two subjects discontinued 
partic ipation after six treatments ot· less d espite n o recorded unto-
wa rd side e ffects. Another discontinue d in th e founh week du e to 
becoming pregn ant. Anoth e r subject obta in e d tanning bed expo-
sure suppleme ntal to the study, and a ll data were dropped after 
initiation of thi s secondary treatm ent. T h e last subject discontinu e d 
treatment after 13 trea t1nents for unknown reasons. 
UV Tanning Treatments To quantify the p h ototherapy expo-
su re, we c alculated the number of tannin g sessions and c umulati ve 
exposure tim e in minutes . T h e mean number of tanning sess ions 
w as 19 ::!:: 7.6 with a m e dian of 19 and range of 3-29 sess ions. 
Parti c ipan ts complete d b e tween 9 and 442 min of phototherapy 
with a mean ( ::!:: SD) of 261 ± 1 42 min. 
Psoriasis Severity Improved With Treatment To determine 
th e effect o n psoriasis of phototherapy w ith a commerc ial tanning 
uni t, we asse ssed psoriasis severity b e fore therapy and after the fin al 
treatmen t. Ini t ial and final psoriasis severi ty m ea sures on a ll 20 
subjec ts are presented in Tables II and III. No psoriasis subject 
comple tely clea re d in the 6-wk study p e riod, but most sh owed 
improvement from baselin e. To pre vent pote n tial bias from fa.iling 
to include subj ec ts who left the study, eJd t data f:i·om all subj ec ts 
were analyzed·. Ana.lysis of all 20 enrolle d subj ects found thai: 16 
(80%) sh owed clini cal response as measure d b y PASI, whereas 17 
(85'%) sh owed SAPASl resp o nse. One subject d ecre ased to a 
minimal SAPASJ score of 0.12 , a score clinica!Jy d.ifticu lt to 
distinguish !Tom cle aring. 
Mean re du ction in PAST severity was 35.4 ± 24.1'Yr>, w hic h was 
comparable to th e mean SAPASI redu ction of 36.2 ± 44 .8%. To 
assess whethe r dropout subjects were diffe rent from subj ects com-
1 Rapp, SR., Exum ML, Feldman SR et nl: Suicide ideation, distress and 
disabiliry associated with psoriasis: a profile of high risk patients. U11p11hlisllcd 
1/ICI/1/ISCript . 
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Table II. T anning Bed Trea tment Improves Psoriasis 
Severity and H ealth-Rela ted Quality of Life Measure s 
Initial Score" Fina l Scorch .Significa nce' 
Severity Measure (n ~ 20) (n = 20) (p value) 
Disea.<e severity 
Psori asis area 7.96 :!: 1.77 5.04 :!: 2.5 0 = .0001 Severity index 
Sclf-admin is tercd 
Psorias is m·ea 11 .8 :!: 4.4 7.9 ::!: 7.7 0 = .02 
Severity index 
Q uality ofLifc 
Psori as.is-related 41.0 :!: J 1.0 24.1 :!: 11.0 0 = .0001 Strcsscr scale 
Brief symptom 0.25 :!: 0.28 0.10 ::!: 0. 13 0 = .02 Inventory 
Perceived stress 29.6 :!: 6.3 26.6 :!: 8.9 o ~ .2 
Total disabili ty 39.8 :!: 8.3 37.4 :!: 4.9 0 = .2 
n lnirj;,) scores represent the mea n ± SD of the o utcome varia ble before the first 
tan ning exposure . 
" Final 'scores represent the mean :!::: SD of the outcome variable after th e fin al 
tanni11g expos ure . 
,. Paired t test. 
pleting the trial, the 15 part1c1pants that compl eted the fi.ll.l 6- w k 
treatm e nt cou rse reduced th eir PAS! by 39.4 :±: 25.3% and SA PASI 
by 52.3 :±: 27 .6%. By con trast, the 5 p articipants w ho did no t 
complete the full treatm en t course decreased th e ir PASI score by 
23 .5 :±: 16 .9% and increased their SAPASI score by 8.74 :±: 55.9%. 
CompariJ1g those w ho comple ted and did no t com ple te the study, 
a t tes t sho w ed no difference between changes in PAS! scores (p = 
0.5) bu t did sho w a significant di fl:e rence between changes in 
SAP AS~ scores (p = 0.05) . . 
Dose-Response Relationship Demonstrated T o confirm 
that the observed improvem ent in psoriasis severity w as due to the 
treatm en t and no t to unre la ted facto rs, we analyzed the r elationship 
between the degree of improvem ent aJ1d th e cumulative exposure . 
[f the improvem ent w as due to tanning bed treatm ents, we expect 
that changes in severity scores would be related to cumulative 
exposure. T he reduction in the PAST aJ1d SAPAST scor~s were highly 
(mea~u1·efunl - m easureinicial) intercorrelated (Pearson R = 0 . 75 , p = 
0.9002). Also, the reduction in the PASI score and SAPASI score 
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adjusted for the baseline score [(measure"""1 - measure;, ;,; ,. 1) / m ea-
sure;,.,;,;,1] were highly in te rcorrelated (Pearson R = 0.65, p = 0.003) . 
T he validi ty o ftb e SAPASI as a measure ofchaJ1ging psorias is seve1i ty 
(responsiveness) has not been assessed in a clinical trial. 
Control of Othe r F a ctors Does Not Influe nce Improve m e nt 
of P soriasis Severity M.ul ti pl e regressio n of the c hange in PAS I 
o n cumlllati've exposure, age, and gender indicated a signi fican t 
eftect of curpulative expos ure , w ith a decrease o f 0. 90 :±: 0 .36 
(slope :±: SE M) PAST units per-hundred tannin g minutes (p = 0.02). 
For the PASI , we fo und no significan t effect for age (0.003 :±: 0.034, 
p = 0.9) o r fem ale sex ( - 1.45 :±: 1.3 1, p = 0 .3). Analogous 
multipl e regression of the chan ge in SAP AS I o n c umulative expo-
sure, age, and gender i1~dicated a signifi can t e fl:ect w ith a dec rease 
of 2 .90 :±: 0.9 SAP AS! uni ts per hundred m inutes (p = 0 .01) . For 
SAPASI, no significant e ffect was o bserved for age (0.035 :±: 0.087, 
p = 0.7) o r female sex ( - 2.44 :±: 3 .36, p = 0.5) . 
Quality of Life Measures Show That Improvement in Pso-
riasis Is Clinically Significant To determine th e clini ca l sig-
nifi cance of reductio n in disease severi ty o bserved in thi s study, we 
collected health-rela ted quali ty of life data by using gene ral an d 
psoriasis- specific m easures . Signifi cant decreases in the m ean B SI 
and PRSS scal es were dem onstrated at the compl eti o n o f the study. 
T he severity of the psychiatri c symptom s (BSI) and th e stressfuln ess 
of psoriasis-rela ted stressors (PRSS) we re decreased afte r tannin g . 
We fo und no sign ifican t elfect on disabili ty (Psoriasis D isabili ty 
Sca le) or perceived stress (Perceived Stress Scale) . 
Side Effects Are Observed But Are Minor Episodes of mild 
pb o totoxic reactio ns occuned in seven of 20 (3 5'Yo) participan ts , 
w ith five expe riencing o ne reaction , and two partic ipan ts each 
eli.'Periencing two and three such reactions, respectively . N o pa-
tients were observed to have a rash , but three rep orted itching after 
o ne tam1ing session and one additional subj ect re ported itchin g 
after two tannin g sessions. 
Subjects Were Satisfied with Treatment At the study com-
pletion , a side e ffect VAS (w here zero represen ted no side effects 
and 1 00 represented m an y side efl:ects) had a m ean respo nse of 
8 .9 :±: 8.1 with minimum of zero and maximum of 35 . For 
trea tmen t satisfactio n (w here zero represen ted not sa tisfi ed and 100 
represented completely sa tisfi ed), we fo und a m ean of 73.0 ::t 28.4 . 
Fifteen had sa tisfac tio n scores greater than 50 . W he n asked 
Table III. Responsiv eness of Psor:iasili Severity in Individual Subjects to Tanning Bed Treatments 
Num ber Cumula tive Initial Fina l t.PAS I Ini tia l Final t.SA I'AS I 
Subject of Doses Exposure (min) PAS I'' PAS J1' (%6.)' SA PAS I" SA PAS I'' ('X, t.)' 
3 9 7.2 5.4 - 1.8 (- 25) 15.4 I 3.4 - 2.0 (- 13) 
2 4 12 6.5 5.0 - 1.5 (- 23) 13.8 18.5 4.7 (+ 34) 
3 19 276 9.0 5. 1 - 9.9 (- 43) 6.6 3.8 - 2.8 (- 443) 
4 6 22 7.0 7.0 0.0 (0) 20.2 32.4 12.2 (+ 60) 
5 16 158 11.1 5.8 - 5.3 (- 48) 15.7 3.3 - 12.4 (- 79) 
6 24 396 5.8 2.5 - 3.3 (- 57) 7.4 2.2 - 5.2 (- 70) 
7 25 342 7.8 5.8 - 2.0 (- 26) 8. 1 6.9 - 1.3 (- 15) 
8 24 409 12.0 4.1 - 7.9 (- 66) 18.1 0.7 - 17.4 (- 96) 
9 27 328 9.4 6.3 - 3.1 (- 33) 12.2 9.2 - 2.9 (- 24) 
10 23 348 7.7 9.4 1.7 (+ 22) 14.5 15 .8 l.3 (+ 9.0) 
11 26 168 5.9 3.9 - 2.0 (- 34) 6.8 1.4 - 5.4 (- 80) 
12 25 314 8.4 3.6 - 4.8 (- 57) 12.6 9.1 3.5 (+28) 
13 19 440 8.2 2.8 - 5.4 (- 66) 10.5 3.7 - 6.7 (- 64) 
14 13 288 8.3 3.9 - 4.4 (- 53) 8.8 6.7 - 2. 1 (-24) 
15 • 25 95 6.4 5.0 - 1.4 (- 22) 7.8 11.0 - 3.2 (+ 41) 
16 17 442 6.4 2.6 - 3.8 (- 59) 6. 1 0. 1 - 5.9 (- 98) 
17 15 360 9.4 5.0 - 4.4 (- 47) 15.9 8:1 - 7.8 (- 49) 
18 21 173 10.1 9.3 - 0.8 (- 8) 17.3 12.8 - 4.5 (- 26) 
19 18 358 6.4 2.8 - 3.6 (- 56) 9.5 5.1 - 4.5 (- 47) 
20 29 283 6.1 5.6 - 0.5 (- 8) 8 2.6 - 5.4 (- 68) 
" Initial scores represent the outcome variable before the fi rst ta nnin g exposure. 
h Final scores represent the o utcome variabl e ~I t the fin al assessmen t ava il abl e. 
r DiflCrcn cc in ini tia l and fin al socrcs with percen t change (0/r16 ) . 
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"Would you recommend tllis treatment to a friend with psoriasis," 
(where zero represented no and 100 represented yes) the mean 
score was 82.9 ± 21.5. Eighteen had recommend scores greater 
than 50. On the subj ective improvem ent VAS completed by 
participants, the mean score was 73.0 ± 25.0. Seventeen had 
improvement scores greater than 50. 
DISCUSSION 
Our brief study suggests that a commercial tanning unit outfitted 
with nonprescription tanning lamps can improve psoriasis severity. 
The amount of improvement was predicted by the number of 
tamling treatments that subjects received, and neither age nor sex 
influenced treatment response. Depending on the measure, for 
those that completed 6 wk of treatment, the disease severity 
decreased by 39-52%. 
We believe the observed improvement is clinically significant. 
Recent short-duration psoriasis studies using betamethasone valer-
ate (Cunliffe et nl, 1992), calcipotriol (Cunliffe et nl, 1992) , dithranol 
(Berth-Jones et nl, 1992), and etretinate (Schopf et nl, 1992) show 
comparable PASI reduction to tllis tanning study. These other 
agents represent typical valuable agents used in our daily clinical 
practice. 
It is difficult to assess the significance of the clinical impact of a 
therapeutic measure by looking at the change in the disease severity 
alone. T he severity of the skin involvement in psoriasis is, however, 
only one way to measure the impact of the condition. R ecent work 
has focused on other dimensions of psoriasis including psyclliatric 
symptoms, perceived stress, functional disability, and satisfaction 
with care . We fow1d that subjects experienced significant improve-
ment in their psyclliatric distress symptoms (BSI), significant de-
creases in the stressfulness of psoriasis (PRSS) , and general satis-
faction with treatment. Thus, tllis treatment modality appears to 
have a positive impact upon several important aspects of the 
health-related quality of life of psoriasis patients and confirms the 
PAS! data that a clinically significant improvement was achieved . 
We were unable to demonstrate a difference in disability or 
perceived stress, however. Disability and perceived stress may be 
harder to reduce with acute changes in disease severity and may be 
affected by chronic severity. We would expect lower disability and 
perceived stress as chronic morbidity decreases. 
We carefully monitored subj ects and observed side effects were 
11linimal. Thirty-five percent of tllis group experienced one to three 
phototoxic reactions during the course of therapy. In our recent 
published retrospective review of psoriasis patients treated in our 
conventional phototherapy facilities, we found that 78 of134 (59%) 
experienced one or more phototoxic reactions during tl1e mean of 
36.2 ± 28.1 sessions (Clark el a /, 1996). In the present study, 
substantiaUy fewer treatments were performed (mean 19 ± 7.6), 
and psoralen photochemotl1erapy and concomitant tar or anthralin 
treatments were not employed. Accordingly, the risk of phototoxic 
reaction appears roughly comparable to conventional phototherapy 
in our hands. This finding of side effect comparability raises the 
question of whether the improvement observed relates more to 
UVB dosing than UV A dosing. Tllis question is not answerable in 
this tria.!, nor is relevant to the finding of improvement. 
None of our subjects developed polymorphic light eruption and 
three (15%) reported having itching after one to three visits. By 
contrast, a previous tamling bed study of 31 English subjects found 
that pruritus occurred in 27 (87%) and polymorpllic light eruption 
occurred in 13 (41 %) (Rivers et nl, 1989). Possible explanations for 
these observed differences might include a difference in the UV 
lamp type used, population differences in susceptibility to polymor-
phic light eruption (Fusaro and Johnson, 1996), and differential 
dosimetry. 
T llis study has a number of strengths. First, each subject had 
separate severity assessments, the PASI and SAPASI. ln effect, 
patients had independent observations of their psoriasis severity 
using the two most validated psoriasis instruments (Feldman et nl, 
1996; Fle ischer and Exum, 1995) . We have previously demon-
strated the stability and responsiveness of the SAPASI over time 
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(Feldman et nl, 1996), suggesting tl1at our observed significant 
changes represent real changes. We found that both instruments 
and an independent health-related quality oflife instrument showed 
statistically significant irnprovement. The influence of recreational 
and therapeutic solar exposure was m.ininlized by conducting tlus 
trial in the winter and early spring. 
There are a number oflimitations to this study. We administered 
our phototherapy treatments not based upon irradiance m.easure-
ments but instead based upon the timer in the tanning unit to 
simulate commw1.ity-based tanning eJ\:periences. Despite tl1.is inex-
act dosimetry, acute side effects such as burning were observed no 
more often than is observed in our conventional phototherapy 
facilities. W e caru1ot comment on the actual quantity of UV A and 
UVB light enlitted from the mlit we tested, as our standard 
phototherapeutic instruments failed to render accurate readings. 
T he greatest lin1.itation of this study is the lack of a control group. 
Identifying appropriate controls are problematic in studies of the 
e ffi cacy ofUV treatment. Our study was desig11ed to minimize the 
problems inherent in studies lacking controls. Careful attention was 
paid to eliminatin g the effects due to changes in tl1erapies and 
changes in season. Despite the careful study design, the lack of a 
control group is a serious concern. 
The data showing a dose-response relationsllip between tlle 
cumulative tanning bed exposure and reduction in severity scores 
strongly supports the contention that the observed effects are due to 
tanning bed treatments. N evertheless, a randomized blinded pla-
cebo-controlled trial would provide better proof of efftcacy. The 
data presented provide a basis for designing such a study with 
sufficient power to show a treatment effect. 
If tamli.ng bed treatments are to be used cli11ically, it would be 
valuable to assess the effectiveness of these units in community 
facilities themselves . For this study, treatments were administered 
under strict medical supervision in a university setting. All photo-
therapy sessions were administered by a phototherapy tech1licia.n or 
experienced physician assistant. Although it is likely that d1ese same 
results would be obtained in community commercial tamung 
facilities, we cannot conclude this from our data . Moreover, all 
nonprescription tanning devices are not identical in spectral output, 
so w e cam1ot infer conclusions about mlits other than the one 
provided by the sponsor, Wolff System Technology. 
These data are intriguing and suggests that a nonprescription 
tamling unit that is readily accessible in the United States may offer 
beneficial effects for psoriasis patients. The conventional wisdom 
that these units offer no benefit to psoriasis patients may not be 
valid . 
Tltis study was suppmted iu pmt by a graut jro111 vVo!O' Syste111 Tecllllology 
CmJ>oratiouw,ic" lwd uo part iu t"e desigu orcouduct of t"e study or iul"e aualysis, 
iutCI]Jrel.ntiou, or repmt iug of res ults. 
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